RecruitingNCT05782335

Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis

Analysis of T and B Cell Repertoire Changes and CTLA4 Genetics and Gene Expression to Understand the Mechanisms of Treatment Response to Orencia ® (Abatacept) in Rheumatoid Arthritis

Sponsor

Hospital for Special Surgery, New York

Enrollment

72 participants

Start Date

Nov 1, 2022

Study Type

OBSERVATIONAL

Conditions

Rheumatoid Arthritis

Summary

The condition that will be studied is Rheumatoid Arthritis (RA), and in particular, RA patients with moderate to highly active disease who were prescribed Abatacept (Orencia®) (ABA) by their physician during their setting of care at Hospital for Special Surgery (HSS). This investigator-initiated, prospective, comparative, 3-arm observational study will examine changes in lymphocytes in RA patients starting abatacept compared to RA patients starting TNF inhibitors and to healthy controls. This will help investigators to learn more about the processes that cause joints to swell and hurt. This may also offer clues that might predict which patients will have a good or poor response to these treatments.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining how abatacept (Orencia) — a medication used to treat rheumatoid arthritis (RA) — affects the immune system over time. Specifically, researchers are tracking changes in immune cells in the blood (T cells and B cells) to better understand why the drug works for some patients and not others. **You may be eligible if:** - You are 18 years old or older with a confirmed diagnosis of rheumatoid arthritis - You are currently on methotrexate (with or without other standard RA medications) and are either about to start abatacept, OR you are on stable RA therapy and may also be using a TNF inhibitor - Your current medications have been stable for at least 4 weeks **You may NOT be eligible if:** - You have recently changed your RA medications - You do not meet diagnostic criteria for rheumatoid arthritis - Your treatment plan has changed in the past 4 weeks Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.